Responses
E-Posters
E-Poster Viewing
EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
Compose a Response to This Article
Other responses
No responses have been published for this article.